| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_34ef52c68d9267a3ebf4c0d592a7cb6e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-34 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
| filingDate |
2017-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_585235b435d4fe81b7ad9f2125e3ee03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ed1034ece1a7376397e408e50c47e1f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8c62983c4019c335d42aef59783f151
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac1c31c7e4c412e56bd20582490aaa5b |
| publicationDate |
2018-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-108794478-A |
| titleOfInvention |
Novel purine derivatives class compound, preparation method, pharmaceutical composition and its pharmaceutical applications |
| abstract |
The invention belongs to field of medicine and chemical technology, it is related to the compound of Formula I inhibited to mammal mTOR signal paths and its pharmaceutical salt or hydrate, the definition of each substituent group is as used in the description in general formula I；The preparation method of compound of Formula I：Including compound of Formula I or the pharmaceutical composition of its officinal salt or hydrate；The purposes of compound of Formula I or its officinal salt or hydrate in producing drug, the drug are dynamic due to disease caused by mTOR path signal unconventionality expressions for treating lactation. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109824701-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109824701-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112707907-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112707907-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021078141-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111875606-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111875606-B |
| priorityDate |
2017-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |